JP7343305B2 - 抗lystによる免疫調整のための組成物及び方法 - Google Patents
抗lystによる免疫調整のための組成物及び方法 Download PDFInfo
- Publication number
- JP7343305B2 JP7343305B2 JP2019098654A JP2019098654A JP7343305B2 JP 7343305 B2 JP7343305 B2 JP 7343305B2 JP 2019098654 A JP2019098654 A JP 2019098654A JP 2019098654 A JP2019098654 A JP 2019098654A JP 7343305 B2 JP7343305 B2 JP 7343305B2
- Authority
- JP
- Japan
- Prior art keywords
- lyst
- inhibitors
- tissue
- vascular
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Child & Adolescent Psychology (AREA)
- Materials Engineering (AREA)
Description
テキストファイルとして2015年5月4日に提出され、「NWCH100 PCT_ST25.txt」という名前で、2015年5月1日に作成され、51,000倍とのサイズを有する配列表は、参照によって本明細書に組み込まれる。
本発明は、米国国立衛生研究所によりChristopher Breuerに授与されたNIH助成金R01 HL098228の下で政府支援によりなされた。政府は本発明の特定の権利を有する。
本発明の分野は、一般に、血管組織再生の増強、ならびに新生内膜過形成および線維増殖性疾患に関連する罹患率および死亡率の軽減のための組成物、デバイス、および方法に関する。
組織修復は、傷害部位の局所炎症促進性細胞由来の刺激性サイトカインシグナル伝達に応答して死細胞または損傷細胞の順序付けた除去および置き換えを容易にする複雑な段階的過程である(Wynn and Baron,Semin Liver Dis.,30(3):245-257(2010);Wynn,Clin.Invest.117:524-529(2007))。しかし、組織修復応答が不適切であるか、例えば、慢性疾患または傷害の繰返しに応答して長期間持続される場合、正常な再生機構が傷害部位での過剰な新組織(neotissue)成長および細胞外基質(ECM)成分の蓄積に起因する病
的状況を生じさせ得る。
することである。
本発明のさらなる目的は、被験体において治癒を促進し、瘢痕形成、癒着、および線維増殖性疾患を阻害するための組成物、方法、およびデバイスを提供することである。
リソソーム輸送制御因子(「LYST」)タンパク質の阻害が組織損傷部位の炎症応答の軽減に関連することを明らかにした。LYSTタンパク質の発現および機能の阻害のための組成物および方法を記載する。組成物および方法は、再生促進性免疫応答を生じるマクロファージ、血小板、およびナチュラルキラー細胞の機能を変更することによる、新生内膜の形成および線維増殖性障害に寄与する免疫過程の調整に有用であり得る。
本発明は、例えば、以下の項目も提供する。
(項目1)
a)被験体における(in a subject in a subject)マクロファージ浸潤の軽減もしくは防止または血小板活性化の軽減もしくは防止に有効な量の1つまたはそれを超えるLYSTのインヒビター;および
b)生理学的に許容され得るキャリア
を含み、
1つまたはそれを超えるLYSTのインヒビターの該量が該被験体における血管新組織の形成を防止しない、薬学的組成物。
(項目2)
0.1mg/kgヒト体重と1000mg/kgヒト体重との間の量の1つまたはそれを超えるLYSTインヒビターを送達する投薬製剤中の項目1に記載の組成物。
(項目3)
マクロファージ浸潤を軽減または防止するのに有効な投薬量の項目1に記載の組成物。
(項目4)
血小板活性化を軽減または防止するのに有効な投薬量の項目1に記載の組成物。
(項目5)
1つまたはそれを超えるLYSTインヒビターが、抗LYST抗体の結合特異性を有する抗体、抗体フラグメント、またはタンパク質である、項目1に記載の組成物。
(項目6)
1つまたはそれを超えるLYSTインヒビターが、アンチセンス分子、siRNA、miRNA、アプタマー、リボザイム、三重鎖形成分子、RNAi、および外部ガイド配列からなる群から選択される機能的核酸である、項目1に記載の組成物。
(項目7)
1つまたはそれを超える機能的核酸が発現ベクターから発現される、項目6に記載の組成物。
(項目8)
ナノ粒子、微粒子、ミセル、エマルジョン、合成リポタンパク質粒子、リポソーム、カーボンナノチューブ、ゲル、またはコーティングからなる群から選択される送達ビヒクルをさらに含む、項目1に記載の組成物。
(項目9)
他の抗新生内膜剤、化学療法剤、ステロイド性および非ステロイド性の抗炎症薬、従来の免疫治療剤、免疫抑制剤、サイトカイン、ケモカイン、および成長因子からなる群から選択される1つまたはそれを超えるさらなる治療剤をさらに含む、項目1に記載の組成物。
(項目10)
項目1~9のいずれか1項に記載の組成物を含む血管グラフトまたは医療デバイス。
(項目11)
前記組成物が前記グラフトまたはデバイス上にコーティングされているか、該グラフトまたはデバイス内に組み込まれている、項目10に記載の血管グラフトまたは医療デバイス。
(項目12)
前記デバイスが、ステント、植込物、針、カニューレ、カテーテル、シャント、バルーン、および弁からなる群から選択される、項目11に記載の医療デバイス。
(項目13)
前記デバイスがステントである、項目12に記載の医療デバイス。
(項目14)
前記ステントが、前記組成物を溶出する薬剤溶出性ステントである、項目13に記載の医療デバイス。
(項目15)
前記グラフトが、自己グラフト、保存自己グラフト、同種異系グラフト、異種グラフト、または合成グラフトである、項目10に記載の血管グラフト。
(項目16)
被験体において瘢痕形成または狭窄を生じさせ得るマクロファージ浸潤を軽減または防止する方法であって、それを必要とする被験体に項目1または3~9のいずれか1項に記載の組成物または項目10~15のいずれか1項に記載のデバイスを投与することを含む、方法。
(項目17)
被験体において動脈血栓症または静脈血栓症を生じさせ得る血小板活性化を軽減または防止する方法であって、それを必要とする被験体に項目1~9のいずれか1項に記載の組成物または項目10~15のいずれか1項に記載のデバイスを投与することを含む、方法。
(項目18)
前記被験体が、再狭窄または他の血管増殖障害のリスクが有るか、再狭窄または他の血管増殖障害を有する、項目16または17に記載の方法。
(項目19)
前記被験体は、血管外傷、血管形成術、血管手術、または移植動脈症を経験していたか、経験しているか、経験する、項目16または17に記載の方法。
(項目20)
前記組成物またはデバイスを、非処置コントロール被験体と比較して、被験体における瘢痕組織の形成の軽減または防止、治癒の促進、肥厚性瘢痕化、ケロイド、または癒着の発症の軽減または防止、肝臓の線維症、肺の線維症、心臓の線維症、または腎臓の線維症の軽減または防止、新生内膜形成、狭窄、または再狭窄の軽減または防止、血栓症の軽減または防止、またはその任意の組み合わせのために使用する、項目16または17に記載の方法。
(項目21)
瘢痕組織の形成の軽減または防止により、ペースメーカー、神経刺激器、置換心臓弁、および人工関節からなる群から選択される1つまたはそれを超えるバイオプロテーゼデバイスの組み込みを促進するが、被包を遮断する、項目16に記載の方法。
(項目22)
瘢痕組織の形成の軽減または防止が、非処置コントロール被験体と比較して、被験体における血管植込物の植込の部位、血管傷害の部位、または手術の部位での新生内膜形成の処置または防止に有効である、項目16に記載の方法。
(項目23)
前記組成物またはデバイスを、非処置コントロール被験体と比較して、被験体における血小板由来成長因子、トランスフォーミング成長因子β、またはその任意の組み合わせの発現を軽減または防止するために使用する、項目17に記載の方法。
(項目24)
血管グラフトの狭窄または再狭窄を軽減する方法であって、被験体への該グラフトの植込前に項目1~10のいずれか1項に記載の組成物で該グラフトをex vivoにて処置することを含む、方法。
I.定義
用語「狭窄」は、血管壁(内皮)傷害後に生じる血管の異常な狭小化をいう。いくつかの実施形態では、狭窄は、50%またはそれを超える管腔外周の減少を含む。用語「再狭窄」は、既存の狭窄部位の狭窄または介入手順使用後の血管の管腔もしくは合成グラフトの狭小化をいう。再狭窄は、本明細書中で使用する場合、閉塞を含む。狭窄または再狭窄に至る例示的な傷害には、アテローム硬化性病変(血管形成術またはステントに伴って認められる)、病変切除(動脈内膜切除に伴って認められる)、外的傷害(例えば、クロスクランピングによる傷害)、または外科的吻合に対する外傷が含まれる。
II.組成物
自然免疫細胞
マクロファージ
血小板
A.LYST
1.LYST遺伝子
2.LYSTタンパク質
C.LYSTのインヒビター
1.抗体
2.機能的核酸
i.アンチセンス分子
ii.アプタマー
iii.リボザイム
iv.三重鎖形成オリゴヌクレオチド
v.外部ガイド配列
vi.RNA干渉
B.賦形剤、送達ビヒクル、およびデバイス
1.非経口投与
、滅菌水、種々のバッファの内容(例えば、Tris-HCl、アセテート、ホスフェート)、pH、およびイオン強度の緩衝食塩水、ならびに、任意選択的に、添加物(界面活性剤および可溶化剤(solubilizing agent)(例えば、ポリソルベート20または80とも呼ばれるTWEEN(登録商標)20、TWEEN(登録商標)80)、抗酸化剤(例えば、アスコルビン酸、メタ重亜硫酸ナトリウム)、および防腐剤(例えば、チメロサール(Thimersol)、ベンジルアルコール)、ならびに増量物質(例えば、ラクトース、マンニトール)など)を含む。非水性の溶媒またはビヒクルの例は、プロピレングリコール、ポリエチレングリコール、植物油(オリーブ油およびトウモロコシ油など)、ゼラチン、および注射用有機エステル(オレイン酸エチルなど)である。製剤を凍結乾燥させ、使用直前に再溶解/再懸濁することができる。製剤を、例えば、細菌保持フィルター(bacteria retaining filter)による濾過、組成物への滅菌剤の組み込み、組成物の照射、または組成物の加熱によって滅菌することができる。
2.肺または粘膜への投与
3.局部投与および経皮投与
4.制御送達マトリックス
5.グラフトおよび医療デバイス
グラフト
組織工学血管グラフト
バイパスグラフト
動静脈グラフト
医療デバイス
ステント
バイオプロテーゼ
IV.使用方法
A.処置すべき障害および疾患
血管増殖性障害
内膜過形成
狭窄
再狭窄
アテローム性動脈硬化症
血管形成術
移植片動脈症
過剰な瘢痕化
肥厚性瘢痕化
ケロイド
癒着
肝硬変
肺線維症
他の線維症性疾患
血小板機能に関連する疾患
B.処置方法
コントロール
グラフトおよびデバイス上のコーティング
C.投薬量および有効量
D.併用療法
実施例1:ベージュ変異は組織グラフトにおける狭窄を軽減する
方法及び材料
組織工学血管グラフト(TEVG)を、ポリ乳酸とポリカプロラクトンとの50:50コポリマーでコーティングしたポリグリコール酸繊維の管から製作された生分解性管状足場上に自己骨髄由来単核球を播種することによって開発した。
結果
方法及び材料
結果
実施例3:ベージュ表現型はLYST遺伝子の変異から生じる
方法及び材料
結果
実施例4:LYST遺伝子のベージュ変異は免疫過程を変化させる
方法及び材料
結果
実施例5:LYSTタンパク質に対する抗体を使用してLYST媒介性免疫調節を行うことができる
方法及び材料
結果
実施例6:機能的Lyst遺伝子を欠くトランスジェニックマウスは、TEVGの狭窄を示さない
方法及び材料
結果
実施例7:Lystは、活性化に応答して血小板機能を調整する
方法及び材料
結果
Claims (2)
- 正常な創傷治癒を防止することなく、被験体において医療植込物の移植に起因するマクロファージ浸潤、瘢痕形成または狭窄を軽減または防止するための医療植込物であって、該医療植込物が、1つまたはそれを超えるリソソーム輸送制御因子(LYST)インヒビターを制御可能に放出する制御放出のナノ粒子、微粒子、リポソーム、ミセル、エマルジョン、ゲルまたはコーティングを、正常な創傷治癒を防止することなく、該被験体において該医療植込物の移植に起因するマクロファージ浸潤、瘢痕形成または狭窄を軽減または防止するのに十分な量で含み、
該1つまたはそれを超えるLYSTインヒビターが、以下:
(i)LYSTタンパク質の機能を阻害することができる抗LYST抗体、
(ii)少なくとも該抗LYST抗体の抗原結合可変ドメインを含み、かつ、該抗LYST抗体の結合特異性を有するタンパク質であって、LYSTタンパク質の機能を阻害することができるタンパク質、ならびに
(iii)LYST遺伝子産物の転写、翻訳または機能を阻害することができる、機能的核酸であるアンチセンス分子、siRNA、miRNA、アプタマー、リボザイム、三重鎖形成分子、RNAi、または外部ガイド配列
のいずれか1つから選択される、医療植込物。 - ステント、グラフトおよび医療植込物からなる群から選択される、請求項1に記載の植込物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461987910P | 2014-05-02 | 2014-05-02 | |
US61/987,910 | 2014-05-02 | ||
JP2016565483A JP6533797B2 (ja) | 2014-05-02 | 2015-05-04 | 抗lystによる免疫調整のための組成物及び方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016565483A Division JP6533797B2 (ja) | 2014-05-02 | 2015-05-04 | 抗lystによる免疫調整のための組成物及び方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019135267A JP2019135267A (ja) | 2019-08-15 |
JP2019135267A5 JP2019135267A5 (ja) | 2019-12-19 |
JP7343305B2 true JP7343305B2 (ja) | 2023-09-12 |
Family
ID=53190038
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016565483A Active JP6533797B2 (ja) | 2014-05-02 | 2015-05-04 | 抗lystによる免疫調整のための組成物及び方法 |
JP2019098654A Active JP7343305B2 (ja) | 2014-05-02 | 2019-05-27 | 抗lystによる免疫調整のための組成物及び方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016565483A Active JP6533797B2 (ja) | 2014-05-02 | 2015-05-04 | 抗lystによる免疫調整のための組成物及び方法 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20170073401A1 (ja) |
EP (1) | EP3137054B1 (ja) |
JP (2) | JP6533797B2 (ja) |
KR (1) | KR102492647B1 (ja) |
CN (1) | CN106456771B9 (ja) |
AU (2) | AU2015252805B2 (ja) |
CA (1) | CA2947494C (ja) |
ES (1) | ES2883837T3 (ja) |
IL (1) | IL248513B (ja) |
RU (1) | RU2728703C2 (ja) |
WO (1) | WO2015168674A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3007631A1 (en) | 2015-12-11 | 2017-06-15 | Research Institute At Nationwide Children's Hospital | Optimized patient specific non-linear tissue engineered vascular grafts |
CN109112211A (zh) * | 2018-05-15 | 2019-01-01 | 广州达瑞生殖技术有限公司 | 一种人类胚胎Chediak-Higashi综合征LYST基因突变检测的引物组合及方法 |
CN112385651A (zh) * | 2020-11-30 | 2021-02-23 | 南开沧州渤海新区绿色化工研究有限公司 | 草铵膦保湿增效组合物及制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002510490A (ja) | 1998-04-03 | 2002-04-09 | キュラジェン コーポレイション | Lystタンパク質複合体およびlyst相互作用タンパク質 |
JP2002514897A (ja) | 1996-02-01 | 2002-05-21 | ユニバーシティ オブ フロリダ | Lyst1およびlyst2の遺伝子組成物ならびに使用方法 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5133732A (en) | 1987-10-19 | 1992-07-28 | Medtronic, Inc. | Intravascular stent |
US5891108A (en) | 1994-09-12 | 1999-04-06 | Cordis Corporation | Drug delivery stent |
DE69622231T2 (de) | 1995-03-01 | 2002-12-05 | Scimed Life Systems Inc | Längsflexibler und expandierbarer stent |
US6821506B2 (en) | 1995-06-08 | 2004-11-23 | Barnes-Jewish Hospital | Site specific binding system, imaging compositions and methods |
US5922554A (en) * | 1995-10-30 | 1999-07-13 | The Regents Of The University Of California | Inhibition of cellular uptake of cholesterol |
US6520983B1 (en) | 1998-03-31 | 2003-02-18 | Scimed Life Systems, Inc. | Stent delivery system |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US6261319B1 (en) | 1998-07-08 | 2001-07-17 | Scimed Life Systems, Inc. | Stent |
US6042597A (en) | 1998-10-23 | 2000-03-28 | Scimed Life Systems, Inc. | Helical stent design |
US8257425B2 (en) | 1999-01-13 | 2012-09-04 | Boston Scientific Scimed, Inc. | Stent with protruding branch portion for bifurcated vessels |
US7220401B2 (en) | 1999-09-24 | 2007-05-22 | Barnes-Jewish Hospital | Blood clot-targeted nanoparticles |
US20080247943A1 (en) | 1999-09-24 | 2008-10-09 | Gregory Lanza | Blood Clot-Targeted Nanoparticles |
EP1132060A2 (en) | 2000-03-09 | 2001-09-12 | LPL Systems Inc. | Expandable stent |
AU2001267075A1 (en) | 2000-06-13 | 2001-12-24 | Scimed Life Systems, Inc. | Disintegrating stent and method of making same |
US6676963B1 (en) | 2000-10-27 | 2004-01-13 | Barnes-Jewish Hospital | Ligand-targeted emulsions carrying bioactive agents |
CZ302719B6 (cs) | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
US7014654B2 (en) | 2001-11-30 | 2006-03-21 | Scimed Life Systems, Inc. | Stent designed for the delivery of therapeutic substance or other agents |
CN100356984C (zh) | 2002-01-24 | 2007-12-26 | 巴内斯-朱威胥医院 | 整联蛋白靶向的影像剂 |
US7789903B2 (en) | 2002-04-04 | 2010-09-07 | Boston Scientific Scimed, Inc. | Stent-graft with adjustable length |
US6986785B2 (en) | 2002-05-03 | 2006-01-17 | Medtronic Vascular, Inc. | Stent balloon assembly and methods of making same |
DE10221076A1 (de) | 2002-05-11 | 2003-11-27 | Ruesch Willy Gmbh | Stent |
US20040002752A1 (en) | 2002-06-26 | 2004-01-01 | Scimed Life Systems, Inc. | Sacrificial anode stent system |
US7144419B2 (en) | 2003-01-24 | 2006-12-05 | Medtronic Vascular, Inc. | Drug-polymer coated stent with blended phenoxy and styrenic block copolymers |
US6918929B2 (en) | 2003-01-24 | 2005-07-19 | Medtronic Vascular, Inc. | Drug-polymer coated stent with pegylated styrenic block copolymers |
US7163555B2 (en) | 2003-04-08 | 2007-01-16 | Medtronic Vascular, Inc. | Drug-eluting stent for controlled drug delivery |
US6945992B2 (en) | 2003-04-22 | 2005-09-20 | Medtronic Vascular, Inc. | Single-piece crown stent |
WO2005011561A2 (en) | 2003-08-04 | 2005-02-10 | Labcoat, Ltd. | Stent coating apparatus and method |
US8298280B2 (en) | 2003-08-21 | 2012-10-30 | Boston Scientific Scimed, Inc. | Stent with protruding branch portion for bifurcated vessels |
US7744645B2 (en) | 2003-09-29 | 2010-06-29 | Medtronic Vascular, Inc. | Laminated drug-polymer coated stent with dipped and cured layers |
EA011822B1 (ru) * | 2003-09-29 | 2009-06-30 | Хемотек Аг | Медицинский продукт, покрытый биологически стабильным полисульфоновым слоем, и способ нанесения покрытия |
US7060090B2 (en) | 2003-10-15 | 2006-06-13 | Medtronic Vascular, Inc. | Stent with increased longitudinal flexibility and scaffolding |
US8157855B2 (en) | 2003-12-05 | 2012-04-17 | Boston Scientific Scimed, Inc. | Detachable segment stent |
US8029815B2 (en) | 2004-04-28 | 2011-10-04 | Elford Howard L | Methods for treating or preventing restenosis and other vascular proliferative disorders |
US7704545B2 (en) | 2004-05-12 | 2010-04-27 | Medtronic Vascular, Inc. | Drug-polymer coated stent |
US8048149B2 (en) | 2004-05-13 | 2011-11-01 | Medtronic Vascular, Inc. | Intraluminal stent including therapeutic agent delivery pads, and method of manufacturing the same |
AU2005326322B2 (en) | 2004-07-01 | 2009-02-05 | Yale University | Targeted and high density drug loaded polymeric materials |
US7323008B2 (en) | 2004-08-09 | 2008-01-29 | Medtronic Vascular, Inc. | Flexible stent |
WO2006096499A2 (en) | 2005-03-04 | 2006-09-14 | Washington University | Mr coronary angiography with a fluorinated nanoparticle contrast agent at 1.5 t |
US7396366B2 (en) | 2005-05-11 | 2008-07-08 | Boston Scientific Scimed, Inc. | Ureteral stent with conforming retention structure |
US8231669B2 (en) | 2005-09-22 | 2012-07-31 | Boston Scientific Scimed, Inc. | Tether guided stent side branch |
AU2006320488A1 (en) | 2005-12-02 | 2007-06-07 | Barnes-Jewish Hospital | Methods to ameliorate and image angioplasty-induced vascular injury |
US8298278B2 (en) | 2006-03-07 | 2012-10-30 | Boston Scientific Scimed, Inc. | Bifurcated stent with improvement securement |
US8348991B2 (en) | 2006-03-29 | 2013-01-08 | Boston Scientific Scimed, Inc. | Stent with overlap and high expansion |
US8066760B2 (en) | 2006-04-18 | 2011-11-29 | Medtronic Vascular, Inc. | Stent with movable crown |
US7678141B2 (en) | 2006-04-18 | 2010-03-16 | Medtronic Vascular, Inc. | Stent graft having a flexible, articulable, and axially compressible branch graft |
CA2650574A1 (en) | 2006-04-27 | 2007-11-08 | Barnes-Jewish Hospital | Detection and imaging of target tissue |
US8236044B2 (en) | 2006-06-30 | 2012-08-07 | Boston Scientific Scimed, Inc. | Stent design with variable expansion columns along circumference |
EP2049141A4 (en) * | 2006-07-21 | 2011-10-26 | Promics Pty Ltd | TREATMENT OF INTIMAL HYPERPLASIA AND ASSOCIATED DISEASES |
US8414637B2 (en) | 2006-09-08 | 2013-04-09 | Boston Scientific Scimed, Inc. | Stent |
US8257431B2 (en) | 2006-11-01 | 2012-09-04 | Boston Scientific Scimed, Inc. | Multi-furcated ePTFE grafts and stent-graft prostheses and methods of making the same |
US8398695B2 (en) | 2006-11-03 | 2013-03-19 | Boston Scientific Scimed, Inc. | Side branch stenting system using a main vessel constraining side branch access balloon and side branching stent |
US8052732B2 (en) | 2006-11-14 | 2011-11-08 | Medtronic Vascular, Inc. | Delivery system for stent-graft with anchoring pins |
US7651527B2 (en) | 2006-12-15 | 2010-01-26 | Medtronic Vascular, Inc. | Bioresorbable stent |
RU2452517C2 (ru) * | 2007-01-30 | 2012-06-10 | Хемотек Аг | Биоразрушаемое средство для поддержания просвета сосудов |
US20100151436A1 (en) | 2007-03-02 | 2010-06-17 | Fong Peter M | Methods for Ex Vivo Administration of Drugs to Grafts Using Polymeric Nanoparticles |
US8187284B2 (en) | 2007-04-23 | 2012-05-29 | Boston Scientific Scimed, Inc. | Intraluminary stent relocating apparatus |
US8372138B2 (en) | 2007-06-12 | 2013-02-12 | Boston Scientific Scimed, Inc. | Shape memory polymeric stent |
US8252048B2 (en) | 2008-03-19 | 2012-08-28 | Boston Scientific Scimed, Inc. | Drug eluting stent and method of making the same |
US8100960B2 (en) | 2008-03-20 | 2012-01-24 | Medtronic Vascular, Inc. | Bloused stent-graft and fenestration method |
US8034099B2 (en) | 2008-03-27 | 2011-10-11 | Medtronic Vascular, Inc. | Stent prosthesis having select flared crowns |
US8414639B2 (en) | 2008-07-08 | 2013-04-09 | Boston Scientific Scimed, Inc. | Closed-cell flexible stent hybrid |
US8414656B2 (en) | 2008-12-05 | 2013-04-09 | Boston Scientific Scimed, Inc. | Porous ureteral stent |
US7942917B2 (en) | 2009-04-17 | 2011-05-17 | Medtronic Vascular, Inc. | Hollow helical stent system |
AU2010339809B2 (en) | 2009-12-17 | 2016-05-05 | The Washington University | Antithrombotic nanoparticle |
US8361140B2 (en) | 2009-12-29 | 2013-01-29 | Boston Scientific Scimed, Inc. | High strength low opening pressure stent design |
US8348993B2 (en) | 2010-03-29 | 2013-01-08 | Boston Scientific Scimed, Inc. | Flexible stent design |
US8353952B2 (en) | 2010-04-07 | 2013-01-15 | Medtronic Vascular, Inc. | Stent with therapeutic substance |
RU2440128C1 (ru) * | 2010-05-17 | 2012-01-20 | Государственное образовательное учреждение дополнительного профессионального образования "Санкт-Петербургская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию" (ГОУ ДПО СПбМАПО Росздрава) | Способ комплексной патогенетической терапии острых форм вирусного гепатита в и микст-гепатитов (в+с, в+d, в+с+d) |
-
2015
- 2015-05-04 CA CA2947494A patent/CA2947494C/en active Active
- 2015-05-04 US US15/308,445 patent/US20170073401A1/en not_active Abandoned
- 2015-05-04 EP EP15723611.8A patent/EP3137054B1/en active Active
- 2015-05-04 JP JP2016565483A patent/JP6533797B2/ja active Active
- 2015-05-04 ES ES15723611T patent/ES2883837T3/es active Active
- 2015-05-04 KR KR1020167033755A patent/KR102492647B1/ko active IP Right Grant
- 2015-05-04 CN CN201580029580.XA patent/CN106456771B9/zh active Active
- 2015-05-04 RU RU2016147083A patent/RU2728703C2/ru active
- 2015-05-04 WO PCT/US2015/029014 patent/WO2015168674A1/en active Application Filing
- 2015-05-04 AU AU2015252805A patent/AU2015252805B2/en active Active
-
2016
- 2016-10-26 IL IL248513A patent/IL248513B/en unknown
-
2018
- 2018-07-13 AU AU2018205184A patent/AU2018205184B2/en active Active
-
2019
- 2019-05-27 JP JP2019098654A patent/JP7343305B2/ja active Active
-
2020
- 2020-11-13 US US17/098,076 patent/US20210238266A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002514897A (ja) | 1996-02-01 | 2002-05-21 | ユニバーシティ オブ フロリダ | Lyst1およびlyst2の遺伝子組成物ならびに使用方法 |
JP2002510490A (ja) | 1998-04-03 | 2002-04-09 | キュラジェン コーポレイション | Lystタンパク質複合体およびlyst相互作用タンパク質 |
Also Published As
Publication number | Publication date |
---|---|
US20170073401A1 (en) | 2017-03-16 |
JP2019135267A (ja) | 2019-08-15 |
CN106456771A (zh) | 2017-02-22 |
AU2015252805B2 (en) | 2018-05-10 |
CA2947494A1 (en) | 2015-11-05 |
US20210238266A1 (en) | 2021-08-05 |
AU2018205184B2 (en) | 2020-04-30 |
CN106456771B (zh) | 2021-06-15 |
AU2018205184A1 (en) | 2018-08-02 |
CA2947494C (en) | 2020-10-20 |
KR102492647B1 (ko) | 2023-01-30 |
AU2015252805A1 (en) | 2016-11-03 |
RU2728703C2 (ru) | 2020-07-31 |
RU2016147083A3 (ja) | 2018-06-05 |
EP3137054B1 (en) | 2021-07-07 |
IL248513B (en) | 2022-02-01 |
WO2015168674A1 (en) | 2015-11-05 |
RU2016147083A (ru) | 2018-06-05 |
BR112016025559A2 (pt) | 2018-01-16 |
IL248513A0 (en) | 2016-12-29 |
CN106456771B9 (zh) | 2021-07-20 |
EP3137054A1 (en) | 2017-03-08 |
KR20170007334A (ko) | 2017-01-18 |
JP2017514844A (ja) | 2017-06-08 |
ES2883837T3 (es) | 2021-12-09 |
JP6533797B2 (ja) | 2019-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210238266A1 (en) | Compositions and methods for anti-lyst immunomodulation | |
O'Brien et al. | Sequential drug delivery to modulate macrophage behavior and enhance implant integration | |
Smith et al. | Harnessing macrophage plasticity for tissue regeneration | |
US8507437B2 (en) | Apoptosis-modulating p53 protein therapy for vascular disorders and nanoparticles containing the same | |
MXPA04002848A (es) | Prevencion y tratamiento de restenosis por administracion local de medicamento. | |
US20220185872A1 (en) | METHOD FOR INHIBITING PLATELET DERIVED GROWTH FACTOR SIGNALING WITH C3aR OR C5aR ANTIBODIES | |
JP2021523103A (ja) | Il−33を含有するマトリックス結合型小胞(mbvs)およびそれらの使用 | |
JP2013506681A (ja) | 腎損傷の処置における使用のための造血幹細胞 | |
Southerland et al. | Gene therapy for the prevention of vein graft disease | |
Li et al. | Vascular smooth muscle cell apoptosis promotes transplant arteriosclerosis through inducing the production of SDF-1α | |
Choi et al. | Lack of additional benefit of intracoronary transplantation of autologous peripheral blood stem cell in patients with acute myocardial infarction | |
WO2014186435A2 (en) | Compositions and methods for reducing neointima formation | |
Sato et al. | G-CSF after myocardial infarction accelerates angiogenesis and reduces fibrosis in swine | |
Palazzolo et al. | Targeting nanotechnologies for the treatment of thrombosis and cardiovascular disease | |
Paneghetti et al. | A novel endothelial-derived anti-inflammatory activity significantly inhibits spontaneous choroidal neovascularisation in a mouse model | |
US20110091486A1 (en) | Inhibition of post-radiation tumor growth | |
BR112016025559B1 (pt) | Composição farmacêutica, enxerto vascular, stent, ou implante, composição para a redução ou prevenção da infiltração de macrófagos, da ativação de plaquetas e de estenose ou reestenose de um enxerto vascular | |
US9233137B2 (en) | Dendritic cell modulation in post-ischemic wounds | |
Mentkowski | Exploring Extracellular Vesicles as Therapeutic Vectors: From Surface Engineering for Enhanced Cardiac Retention to Immunomodulation | |
WO2017149291A1 (en) | Interleukin-4 (il-4) for use in the treatment of myocardial infarction | |
Bashmail | The fabrication of PLGA-Fe3O4-magnetic nanoparticles for targeted delivery of γ-secretase inhibitors to vascular stents | |
Sacar et al. | Antioangiogenic therapy for cardiovascular diseases | |
Beohar et al. | Cytokine treatment for cardioprotection and cardiac regeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190626 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191101 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200713 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201012 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210610 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220308 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220308 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220315 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220316 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20220428 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20220506 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230831 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7343305 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |